Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan ‒tadalafil in pulmonary arterial hypertension

Upfront combination therapy with ambrisentan and tadalafil has been reported to improve the condition of patients with pulmonary arterial hypertension (PAH) more than with either drug alone. However, little is known about the long-term associated changes in hemodynamics and risk assessment scores.

Source: The Journal of Heart and Lung Transplantation - August 27, 2020 Category: Transplant Surgery Authors: Michele D'Alto, Roberto Badagliacca, Francesco Lo Giudice, Paola Argiento, Gavino Casu, Marco Corda, Michele Correale, Stefano Ghio, Alessandra Greco, Mariangela Lattanzio, Valentina Mercurio, Giuseppe Paciocco, Silvia Papa, Renato Prediletto, Emanuele Ro Tags: ORIGINAL CLINICAL SCIENCE Source Type: research